Denmark-based Lundbeck cannot recover damages for the alleged infringement of its Lexapro patent by generic drug companies that it dropped its claims against, a judge has found.
Juno Pharmaceuticals has resolved its appeal of an IP Australia ruling that allowed Seattle-based Juno Therapeutics to extend protection of its namesake trade mark into Australia.
Teva has taken generic drug maker Pharmacor to court for allegedly threatening to infringe its patent for a Parkinson’s drug.
International law firm Jones Day has expanded its intellectual property team in Sydney, hiring experienced patent litigator Andrew Rankine from Ashurst as its second local partner.
Aged care service providers have been put on notice that they could face legal action for blocking whistleblowers from providing evidence to the aged care royal commission.
The Full Federal Court has expedited an appeal filed Christmas Eve by Sanofi-Aventis of a ruling that denied its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
Generic drug maker Sandoz is challenging a ruling that it infringed a patent behind Lundbeck’s blockbuster antidepressant Lexapro, reviving a 15-year fight over the lucrative intellectual property.
French pharmaceutical giant Sanofi has appealed a judge’s ruling denying its bid to block Alphapharm from listing an insulin injector pen on the Pharmaceutical Benefit Scheme.
Johnson & Johnson unit Ethicon is seeking a class closure order in the pelvic mesh class action, as the company prepares to enter mediation.
The Australian Competition and Consumer Commission has lost an appeal of a ruling that dismissed its case over allegedly inadequate disclosures by private health insurer Medibank relating to member benefits.